Open Access 01-12-2022 | Kidney Transplantation | Study protocol
Long-term efficacy and safety of SARS-CoV-2 vaccination in patients with chronic kidney disease, on dialysis or after kidney transplantation: a national prospective observational cohort study
Published in: BMC Nephrology | Issue 1/2022
Login to get accessAbstract
Background
Methods
Results
Conclusion
Trial registration
-
COVID-19 has devastating impact on patients with CKD stages G4-G5, on dialysis or after kidney transplantation.
-
Effective SARS-CoV-2 vaccination is very important in these vulnerable patient groups.
-
Recent studies on vaccination in these patient groups are small short-term studies with surrogate endpoints.
-
Assessment of incidence and course of COVID-19 after various types of SARS-CoV-2 vaccination during a two-year follow-up period in not only patients on dialysis or kidney transplant recipients, but also in patients with CKD stages G4-G5.
-
Quantitative analysis of antibody response after SARS-CoV-2 vaccination and its relationship with incidence and course of COVID-19 in patients with CKD stages G4-G5, on dialysis or after kidney transplantation compared with a control group.
-
Monitoring of (serious) adverse events and development of anti-HLA antibodies.
-
Publication of the study design contributes to harmonization of SARS-CoV-2 vaccine study
-
Data on efficacy of SARS-CoV-2 vaccination in patients with CKD will provide guidance for future vaccination policy.